[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355426-105":59,"doc-detail-355426-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","trop2claudin-program-mediates-immune-exclusion-to-impede-checkpoint-blockade-in-breast-cancer-accepted-25-march-2026","TROP2/claudin program mediates immune exclusion to impede checkpoint blockade in breast cancer - Accepted 25 March 2026","","Immune exclusion restricts antitumor immunity and limits response to immunotherapy, yet its mechanisms remain insufficiently defined. In triple-negative breast cancer (TNBC), an immune-cold microenvironment is linked to poor prognosis and reduced sensitivity to chemotherapy and immune checkpoint inhibitors. This study investigated how TROP2 and claudin-associated tight junction regulation govern immune infiltration, demonstrating barrier-mediated exclusion, predictive biomarker value, and enhanced anti-PD-1 effects when targeting TROP2 with ADC components.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/trop2claudin-program-mediates-immune-exclusion-to-impede-checkpoint-blockade-in-breast-cancer-accepted-25-march-2026/355426/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/trop2claudin-program-mediates-immune-exclusion-to-impede-checkpoint-blockade-in-breast-cancer-accepted-25-march-2026/355426.png","ImageObject",300,407,{"name":92,"@type":93},"Kyle","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-11","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address in triple-negative breast cancer?","Question",{"text":112,"@type":113},"The study addresses how immune exclusion limits antitumor immunity and causes poor responses to immunotherapy in TNBC, where the immune-cold microenvironment is associated with resistance.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did the researchers investigate immune infiltration in TNBC?",{"text":117,"@type":113},"They used spatial transcriptomic analysis comparing immune-enriched versus immune-cold treatment-naïve TNBC, followed by functional loss-of-function and reconstitution experiments and a humanized TROP2 syngeneic TNBC model.",{"name":119,"@type":110,"acceptedAnswer":120},"What role does TROP2 play according to the findings?",{"text":121,"@type":113},"TROP2 regulates barrier-mediated immune exclusion by controlling claudin 7 association and tight junction regulation, inversely correlating with T-cell infiltration and promoting tumor progression in vivo.",{"name":123,"@type":110,"acceptedAnswer":124},"How does TROP2 targeting affect response to anti-PD-1 therapy?",{"text":125,"@type":113},"Targeting TROP2 via hRS7, the antibody component of sacituzumab govitecan, enhances anti-PD-1 response by improving T-cell accessibility and effector function, and TROP2 expression is associated with lack of response to anti-PD-1 in human breast cancer.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},355426,1790317751,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":36,"preview_page_count":19,"preview_urls":149},3985741905716,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Open access Original research  \nTROP2/claudin program mediates immune exclusion to impede checkpoint blockade in breast cancer  \nBogang Wu  ,1,2 Win Thant,1,2 Elena Bitman,1 Ting Liu,1 Jie Liu,2,3  \nEleftherios I Paschalis,3 Bidish K Patel,1 Cole Nawrocki,1 Katherine H Xu,1 Linda T Nieman,1 David T Ting,1 Bruna de Gois Macedo,2 Yang Cheng,2  \nKevin Jiang,1 Fengfei Sun,4 Nayana Thimmiah,1 Sheng Sun,1 Rachel O Abelman,1 Veerle I Bossuyt,1 Steven J Isakoff,1 Laura M Spring,1 Aditya Bardia,1  \nLeif W Ellisen1,5  \nTo cite: Wu B, Thant W, Bitman E, et al. TROP2/claudin program mediates immune exclusion to impede checkpoint blockade in breast cancer. Journal for ImmunoTherapy of Cancer 2026;14:e012265 . doi:10.1136/jitc-2025-012265  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[jitc-2025-012265](jitc-2025-012265)) .  \nAccepted 25 March 2026  \n© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \nFor numbered affiliations see end of article.  \nCorrespondence to  \nDr Leif W Ellisen;  \n[lellisen@mgh.harvard.edu](lellisen@mgh.harvard.edu)  \nDr Bogang Wu;  \n[wu.bogang@mayo.edu](wu.bogang@mayo.edu)  \nABSTRACT  \nBackground Immune exclusion inhibits antitumor immunity and response to immunotherapy, but its mechanisms remain poorly defined. In triple-negative breast cancer (TNBC), an aggressive and generally immune-rich subtype, an immune-cold microenvironment predicts poor prognosis due to a limited response to chemotherapy and immune checkpoint inhibitors. This study aimed to identify mechanisms regulating immune infiltration in TNBC.  \nMethods We performed spatial transcriptomic analysis comparing immune-enriched versus immune-cold treatment-naïve TNBCs. Functional analyses, including loss-of-function and reconstitution experiments, were conducted to investigate the role of trophoblast cellsurface antigen 2 (TROP2), a key target of anticancer antibody drug conjugates (ADCs), in promoting TNBC progression. A humanized TROP2 syngeneic TNBC model was used to assess the effects of TROP2-targeting in combination with anti-programmed cell death protein 1 (PD-1) therapy. Additionally, data from patients treated with immune checkpoint blockade were used to test hypotheses from the preclinical findings.  \nResults We reveal that TROP2 controls barrier-mediated immune exclusion in TNBC through claudin 7 association and tight junction regulation. TROP2 expression is inversely correlated with T-cell infiltration and predicts poor outcomes in TNBC. We demonstrate that TROP2 is sufficient to drive tumor progression in vivo in a CD8 T cell-dependent manner, while its loss deregulates expression and localization of multiple tight junction proteins, enabling T-cell infiltration. We show that TROP2 targeting via hRS7, the antibody component of the ADC sacituzumab govitecan, enhances the anti-PD-1 response and improves T-cell accessibility and effector function. Correspondingly, TROP2 expression is highly associated with lack of response to anti-PD-1 therapy in human breast cancer.  \nConclusions This study defines a new mechanism of barrier-mediated immune exclusion in cancer controlled by TROP2-dependent tight junctions. This mechanism drives tumor progression but can be targeted via TROP2-directed therapy to activate antitumor immunity and enhance immunotherapy response.  \nWHAT IS ALREADY KNOWN ON THIS TOPIC  \n\n| ⇒ Barrier-mediated immune exclusion is emerging asa mechanism of immune evasion in cancer such as triple-negative breast cancer (TNBC), but its molecular underpinnings remain poorly understood. Trophoblast cell-surface antigen 2 (TROP2) is a surface glycoprotein targeted by antibody-drug conjugates such as sacituzumab govitecan, yet its functional role beyond drug delivery has been unclear.\u003Cbr>WHAT THIS STUDY ADDS |\n","cbCaipRlrTyQNoSj","https://ap.wps.com/l/cbCaipRlrTyQNoSj","pdf",17844802,16,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# What is already known on this topic\n# What this study adds\n# How this study might affect research, practice or policy\n# Introduction","[{\"question\":\"What problem does the study address in triple-negative breast cancer?\",\"answer\":\"The study addresses how immune exclusion limits antitumor immunity and causes poor responses to immunotherapy in TNBC, where the immune-cold microenvironment is associated with resistance.\"},{\"question\":\"How did the researchers investigate immune infiltration in TNBC?\",\"answer\":\"They used spatial transcriptomic analysis comparing immune-enriched versus immune-cold treatment-naïve TNBC, followed by functional loss-of-function and reconstitution experiments and a humanized TROP2 syngeneic TNBC model.\"},{\"question\":\"What role does TROP2 play according to the findings?\",\"answer\":\"TROP2 regulates barrier-mediated immune exclusion by controlling claudin 7 association and tight junction regulation, inversely correlating with T-cell infiltration and promoting tumor progression in vivo.\"},{\"question\":\"How does TROP2 targeting affect response to anti-PD-1 therapy?\",\"answer\":\"Targeting TROP2 via hRS7, the antibody component of sacituzumab govitecan, enhances anti-PD-1 response by improving T-cell accessibility and effector function, and TROP2 expression is associated with lack of response to anti-PD-1 in human breast cancer.\"}]","TROP2/claudin program mediates immune exclusion to impede checkpoint blockade in breast cancer - Accepted 25 March 2026 | PDF",1790118759,[150,154,158,162],{"page_no":8,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/615815dbec2c56165f0e23e234bf5c4f.webp",983,1310,{"page_no":14,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c25f7c58ab4a9a5878a95f7c6561b7d6.webp",982,1309,{"page_no":81,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/714049e26908d44956cbb777e263a44b.webp",981,1308,{"page_no":19,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1703e1a1dd0f8480fe0cb0343642a9b5.webp",980,1306]